TL;DR
Get beauty and skincare favorites delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Amorepacific Ventures has invested in biotechnology company Junevity and signed a separate licensing agreement covering cosmetic applications of Junevity’s RESET Platform. The companies plan to investigate skin-ageing pathways; Amorepacific is slated to develop and commercialise any resulting cosmetics, but no products, launch dates or investment terms were disclosed.
Amorepacific Ventures, the corporate investment arm of South Korean beauty company Amorepacific, has invested in biotechnology firm Junevity and entered a separate licensing agreement for cosmetic applications of Junevity’s technology. The companies say they will research skin-ageing pathways with the aim of informing future cosmetics, though they have not announced a product, development timetable or investment value.
Under the collaboration, Junevity will use its RESET Platform to investigate biological pathways associated with skin ageing. The companies plan to combine Junevity’s target-discovery technology with Amorepacific’s knowledge of skin biology, cosmetic development and commercialisation. The stated focus is identifying pathways that may be suitable for cosmetic applications, including research into skin gene networks.
Amorepacific will lead product development and commercialisation for cosmetics arising from the work. Junevity, meanwhile, will continue advancing therapeutic applications of its platform, according to the source report. The arrangement therefore covers a cosmetics-focused collaboration alongside Junevity’s separate therapeutic work; the report does not describe a clinical trial or a confirmed treatment for skin ageing.
Amorepacific R&I Center chief technology officer Brian Byung-Fhy Suh said the research would examine gene networks and transcriptional regulation in skin ageing. Junevity co-founder and chief executive John Hoekman described the agreement as a way to explore the platform in skin care and extend its reach into another market. Neither company disclosed the investment amount, licensing terms or specific research milestones in the report.
A Biotech Route Into Skin Care
The deal connects a biotechnology platform focused on target discovery with a major cosmetics company that has the capacity to develop and sell skin-care products. If the joint research identifies pathways that can be translated into cosmetic ingredients or formulations, Amorepacific would oversee the route from research toward commercial products. That possibility remains an objective, not an announced outcome.
For Junevity, the agreement creates a cosmetics application for technology it also uses in therapeutic research. For Amorepacific, it adds a research partnership aimed at understanding the biology of skin ageing rather than relying only on product development within its own organisation. Consumers should not read the announcement as evidence that a new product is available or that the proposed approach has demonstrated an effect on skin.
As an affiliate, we earn on qualifying purchases.
Two Different Research Tracks
Amorepacific is the parent company of skin-care brand Laneige and operates a corporate venture arm, Amorepacific Ventures. The reported investment was made by that venture arm, while the separate licensing agreement relates to cosmetic field applications. The source does not state whether the investment and licence were signed at the same time or give further financial details.
Junevity’s work spans both cosmetic and therapeutic research, but the companies describe distinct roles in this collaboration. Their joint work concerns potential cosmetic applications; Junevity will continue its therapeutic pipeline independently. Hoekman cited a lead siRNA candidate for obesity that he said was headed into human clinical trials. That is a statement about Junevity’s therapeutic programme, not a clinical milestone for the skin-care partnership.
““The next-generation of skin health innovations will be informed by deeper research-driven insights into the biology of skin ageing, particularly the role of gene networks and transcriptional regulation in longevity.””
— Brian Byung-Fhy Suh, chief technology officer of Amorepacific R&I Center
As an affiliate, we earn on qualifying purchases.
No Products or Milestones Disclosed
The source report does not provide the investment amount, licensing fee, research schedule or development milestones. It also does not identify a specific ingredient, formulation or product that will result from the work. There is no announced launch date, and it is not clear when the companies expect to report research findings.
The companies describe an effort to discover pathways relevant to cosmetic applications, but the report supplies no study data showing that the platform can change skin gene networks or produce a particular consumer benefit. Any eventual product claims, regulatory status and evidence supporting them remain unknown. The obesity candidate mentioned by Junevity is part of its therapeutic pipeline and should not be confused with the cosmetics research.
As an affiliate, we earn on qualifying purchases.
Research Before Any Product Launch
The immediate next step is the companies’ joint research using Junevity’s RESET Platform and Amorepacific’s skin-science and product-development capabilities. If they identify pathways they consider suitable for cosmetic use, Amorepacific is expected to lead development and commercialisation. The source gives no timetable for those stages or for a public update.
Further details to watch for include research findings, the criteria used to select cosmetic targets, and whether the companies disclose a development programme or product candidate. Until such information is reported, the announcement signals a research and licensing partnership rather than a confirmed new skin-care product.
cosmetic products targeting skin aging
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What has Amorepacific invested in?
Amorepacific Ventures invested in biotechnology company Junevity. The report does not disclose the investment amount or other financial terms.
What will the companies research?
They plan to use Junevity’s RESET Platform to investigate skin-ageing pathways and identify possible cosmetic applications, drawing on Amorepacific’s skin biology and product-development expertise.
Does the partnership mean a new product is coming soon?
No product or launch date has been announced. The companies have described joint research; Amorepacific would lead development and commercialisation if the work leads to cosmetics.
Is Junevity’s obesity research part of the cosmetics deal?
The source describes the obesity programme as part of Junevity’s therapeutic pipeline, separate from the skin-care collaboration. CEO John Hoekman said its lead siRNA candidate was headed into human clinical trials.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
